Elevate your career in Life Sciences:
RIT's Online Executive MBA with Life Sciences Electives.
Entreprenuership
Leadership Development
Biomedical Engineering
Bioinformatics
By combining the strengths of RIT’s highly regarded Executive MBA program with our first-in-class technical curriculum, the Executive MBA with Life Science Electives program is uniquely positioned to help you put your ideas into action. Merging both traditional EMBA coursework with a focus on the life sciences industry allows students to integrate the core competencies found in business, entrepreneurship, and technology commercialization within life sciences-related disciplines, positioning you as a leader in bringing technologies to market.
Program Cadence
The online executive MBA’s cadence is 2 online courses simultaneously for 6 weeks over 16 months with some experiential in-person exceptions.
Experiential exceptions for the Spring 2025 start include:
- In-person orientation on RIT campus in Rochester, NY (Early January 2025)
- 1 day life sciences entrepreneurship seminar (virtual, timing varies)
- 3 day NYC Life Sciences trip (Mid Year 2025)
- 7-10 day International Trip, October 2025 (Life sciences students are welcome to join for experiences, international business class is optional)
2024 EMBA Class Profile
2024 EMBA Class Profile
Scholarship, Aid, & Admission
- Nearly 40% of admitted students receive full or partial funding from employers.
$25,000 average scholarship awarded to accepted students.
$2,500 Decision Scholarship guaranteed with accepted admission by November 25, 2024 for the January 2025 Online Executive MBA program.
Accepted decisions require all application materials be submitted and a formal interview with Program Co-Directors conducted by November 15, 2024. Begin your application today.
- Notable achievements (community service, leadership, within or outside work)
- Financial need (availability of company sponsorship / reimbursement, etc.)
- Personal statement: Focusing on how an EMBA will achieve personal and professional goals, and the scholarship question about what you would accomplish if money were no object.
- GPAs may come into consideration
Customized Learning Outcomes
Core business curriculum includes organizational and personal leadership development, strategic thinking, negotiations, and managing tech innovation.
Life sciences electives typically replace the executive leadership, international finance and international business courses.
Their cadence slightly differs from Executive MBA courses as they are taught in partnership with our RIT Colleges of Sciences and Engineering:
BIOL 625 Ethics in Bioinformatics
This course will be focused on individual and organizational responsibilities in bioinformatics research, product development, product commercialization and clinical and consumer genetic testing. Tentative schedule: Fall 2025, approximately 7-15 weeks depending on scheduled format.
BIME Graduate Biodesign
This course is a graduate-level introduction to the biodesign process used for innovating medical technologies. Student teams will apply a needs-based assessment strategy to identify opportunities in a biomedical-related field such as assistive technologies and rehabilitation engineering. Incorporating CAD will culminate in a virtual medical device prototype. Concepts of intellectual property, regulatory considerations, reimbursement, and business models will be introduced. Tentative schedule: Fall 2025, approximately 7-15 weeks depending on scheduled format.
BIME 617 Principals of Biomedical Device Regulations
This course will present the principles and fundamentals of medical device and in vitro diagnostic regulation. The course will cover the history of the FDA and the regulations around food, drug, and cosmetic products. An overview of regulatory pathways, clinical trials, good manufacturing practices, and quality system design will be covered. Comparisons between the US, EU, and other international regulatory bodies will also be discussed. The course will culminate with students developing a clinical trial and regulatory strategy for a new hypothetical medical device. Tentative schedule: Fall 2025, approximately 7-15 weeks depending on scheduled format.